Angiochem to Present New Clinical Data for ANG1005 in Brain Cancers at Society for Neuroscience Meeting.ANG ANG In currencies, this is the abbreviation for the NL Antillian Guilder. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 1005 and Angiochem's EPiC platform to be Highlighted at Conference MONTREAL & CHICAGO -- Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier blood-brain barrier n. Abbr. BBB A physiological mechanism that alters the permeability of brain capillaries so that some substances, such as certain drugs, are prevented from entering brain tissue, while other substances are allowed to to treat brain diseases, announced today that clinical data for its lead drug candidate, ANG1005, for the treatment of brain cancers, as well as data showing how compounds from Angiochem's Engineered Peptide Compounds (EPiC) platform are capable of crossing the blood-brain barrier will be highlighted at the Society for Neuroscience For other uses, see SFN (disambiguation). The Society for Neuroscience (SfN) is a professional society for basic scientists and physicians around the world whose research is focused on the study of the brain and nervous system. Annual Meeting in Chicago on October 17-21, 2009. In addition to poster presentations, ANG1005 and Angiochem's EPiC platform will be the subject of a Society for Neurosciences-sponsored press conference, entitled "Crossing the Blood-Brain Barrier." Angiochem will also be sponsoring a scientific symposia discussing new therapeutic approaches to crossing the blood-brain barrier. ANG1005 is a novel, next-generation taxane derivative, targeting the LRP LRP Lipoprotein Receptor-Related Protein LRP Low Density Lipoprotein Receptor-Related Protein LRP Loan Repayment Program LRP Linux Router Project LRP Livestock Risk Protection LRP Laparoscopic Radical Prostatectomy Lrp Leucine-responsive Regulatory Protein pathway to cross the blood-brain barrier and reach therapeutic concentrations in the brain. ANG1005 is in two separate Phase 1/2 clinical studies in patients with brain cancers and cancer metastases Metastasis (plural, metastases) A tumor growth or deposit that has spread via lymph or blood to an area of the body remote from the primary tumor. Mentioned in: Malignant Melanoma . The drug was created with Angiochem's Engineered Peptide Compound (EPiC) platform which harnesses the naturally-occurring LRP (low-density lipoprotein low-density lipoprotein n. Abbr. LDL A lipoprotein that contains relatively high amounts of cholesterol and is associated with an increased risk of atherosclerosis and coronary artery disease. receptor-related protein) receptors on the surface of the blood-brain barrier. The schedule is as follows: * Society for Neuroscience Press Conference: Sunday, October 18, 2009, 11:00 a.m., "Crossing the Blood-Brain Barrier", McCormick Place McCormick Place is an enormous exposition complex located in Chicago, Illinois. Conference Center, South 501D. * Poster Presentation #185.1: Sunday, October 18, 8 a.m. - 12 p.m., "Development Of A New Engineered Peptide Compound (EPiC) Platform For The Transport Of Small And Large Therapeutics To The CNS See Continuous net settlement. CNS See continuous net settlement (CNS). ", Gabathuler, et.al., McCormick Place Conference Center, South Hall A. * Poster Presentation #185.6: Sunday, October 18, 8 a.m. - 12 p.m., "Development Of A New Engineered Peptide Compound (EPiC) For The Treatment Of Malignant Glioma glioma /gli·o·ma/ (gli-o´mah) a tumor composed of neuroglia in any of its states of development; sometimes extended to include all intrinsic neoplasms of the brain and spinal cord, as astrocytomas, ependymomas, etc. ", Drappatz, et.al., McCormick Place Conference Center, South Hall A. * Poster Presentation #185.2: Sunday, October 18, 8 a.m. - 12 p.m., "ANG1005: A promising new Engineered Peptide Compound (EPiC) for patients with advanced solid tumors and brain metastases brain metastases Oncology Cancer that has spread from a primary tumor, most commonly, small cell carcinoma of the lung, to the brain ", Kurzrock, et. al., McCormick Place Conference Center, South Hall A. * Scientific Breakfast Symposia: Monday, October 19, 6:30 - 8:30 a.m., "Crossing The Blood-Brain Barrier: New Therapeutic Approaches", Hyatt Regency McCormick Place, Room CC10CD - Level 1. This scientific symposia includes presentations and Q&A with leading scientific, medical and industry experts in the areas of CNS and oncology. The event will also be webcast and available on the Angiochem website at: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=232273&eventID=2482177 About ANG1005 // ANG1005 is a novel, next-generation taxane derivative targeting the LRP pathway. ANG1005 was engineered with the EPiC platform which was designed to cross the blood-brain barrier (BBB BBB A medium grade assigned to a debt obligation by a rating agency to indicate an adequate ability to pay interest and repay principal. However, adverse developments are more likely to impair this ability than would be the case for bonds rated A and above. ). Studies have shown that ANG1005 gains entry into the brain compartment by targeting the low-density lipoprotein receptor-related protein (LRP) which is one of the most highly expressed receptors on the surface of the BBB. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP, which is upregulated in various cancer cells including gliomas and metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. brain cancers. About Angiochem // Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are uniquely capable of crossing the blood-brain barrier (BBB) to treat brain diseases. The company's proprietary Engineered Peptide Compounds (EPiC) technology creates drugs that cross the BBB and reach therapeutic concentration in the brain, by harnessing naturally-occurring receptors on the surface of the BBB. Angiochem's lead product candidate, ANG1005 is in two separate Phase 1/2 clinical studies in patients with brain cancers and cancer metastases. Additionally, Angiochem is developing a deep and broad product pipeline, including small and large molecules, for the potential treatment of a wide range of CNS diseases, including neurodegenerative and metabolic diseases, brain cancer, psychiatric disorders and many others. Founded in 2006, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com. Copyright 2009 Angiochem, Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion